Bernard Davitian, MBA, Appointed EVP & CFO Of Fovea Pharmaceuticals

PARIS, October 17, 2006 – Fovea Pharmaceuticals SA, a biopharmaceutical company specializing in the discovery, development and commercialization of innovative drugs for the treatment of ocular diseases, with special focus on retinal pathologies, announced today it has appointed Bernard Davitian as Executive Vice-President and Chief Financial Officer. Bernard Davitian reports to Bernard Gilly, Fovea’s Chief Executive Officer.